Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Sponsor: Revolution Medicines, Inc.
Summary
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Official title: Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
604
Start Date
2023-09-07
Completion Date
2027-04-30
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
RMC-9805
Oral Tablets
RMC-6236
Oral Tablets
Locations (17)
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
Smilow Cancer Hospital (Yale University)
New Haven, Connecticut, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Lee Moffitt Cancer Center
Tampa, Florida, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
NYU Langone
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke Cancer Center
Durham, North Carolina, United States
Carolina BioOncology Institute
Huntersville, North Carolina, United States
The Christ Hospital
Cincinnati, Ohio, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, United States
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States
START
San Antonio, Texas, United States
NEXT Oncology Virginia
Fairfax, Virginia, United States